Alzheimer Europe

Alzheimer Europe

Alzheimer Europe

145, route de Thionville
L-2611 Luxembourg

Project Leader

Mr. Georges Jean

Mr. Georges Jean
Phone: +352 297970
Fax: +352 297972



Project Staff

Mr. Alex Teligadas

Mr. Alex Teligadas
Communications Officer
Phone: +352 2040 7972

Organisation Presentation

Alzheimer Europe (AE) is an NGO aiming to raise awareness of all forms of dementia. AE is based in Luxembourg and operates a common European platform through co-operation among 33 Alzheimer organisations in Europe:

 Alzheimer Europe (AE)


AE is a source of information on all aspects of dementia, including:

Yearbooks & research reports

Each year, AE publishes reference books concentrating on particular aspects of dementia. The latest yearbook, published in December 2011, outlines the legal provisions relating to the restriction of freedom of people with dementia in Europe.

AE's newest research report addresses some of the main ethical issues linked to carrying out dementia research in an ethical manner.

Dementia in Europe Magazine

Triannual publication with a circulation of 3,500, including Members of the European Parliament and Commission and also national policy makers.


  • Monthly e-publication reaching 4,200+ contacts
  • 2011: 443 total articles in 11 issues


  • Source of news and information about dementia
  • E-shop for yearbooks, magazines, care manuals
  • Host to PharmaCog project web presence
  • 164,000+ unique visitors in 2010

Annual conference

AE's annual conference attracts people with a wide spectrum of backgrounds within the field of dementia. This includes people with dementia, their carers, representatives of national Alzheimer associations, healthcare professionals, academics and researchers, as well as policy makers. In 2011, some 470 delegates from nearly 40 countries participated in Alzheimer Europe’s 21st Conference in Warsaw.

European research projects

Besides NILVAD, Alzheimer Europe is also a partner in the following European research projects:

PharmaCog: Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development

  • IMI project, EUR 27.7 mill. funding
  • 5 year duration: Jan. 2010 - Jan. 2015
  • 30 partners, led by GlaxoSmithKline and University of Marseille
  • Industry/academic cooperation to develop biomarkers and drugs for AD

DECIDE: Diagnostic Enhancement of Confidence by an International Distributed Environment

  • FP7 project, EUR 2.4 million funding
  • Duration: Sept. 2010 - March 2013
  • 13 partners, led by GARR Consortium
  • E-infrastructure to aid early AD diagnosis